My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 140

    1.

    Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.

    Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang WC, Reinhardt RR.

    Diabetes Care. 2002 Mar;25(3):439-44.PMID: 11874927 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.

    Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM; Insulin Aspart Pediatric Pump Study Group.

    Diabetes Care. 2008 Feb;31(2):210-5. Epub 2007 Nov 5.PMID: 17989308 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.

    Hanaire-Broutin H, Melki V, Bessières-Lacombe S, Tauber JP.

    Diabetes Care. 2000 Sep;23(9):1232-5.PMID: 10977011 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.

    Bode BW, Strange P.

    Diabetes Care. 2001 Jan;24(1):69-72.PMID: 11194244 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.

    Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R.

    Diabetes Care. 1999 May;22(5):784-8.PMID: 10332682 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump.

    Raskin P, Holcombe JH, Tamborlane WV, Malone JI, Strowig S, Ahern JA, Lavent F.

    J Diabetes Complications. 2001 Nov-Dec;15(6):295-300.PMID: 11711322 [PubMed - indexed for MEDLINE]Related articles

    7.

    Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.

    Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, Selam JL, Home PD.

    Diabetes Care. 2009 Jul;32(7):1170-6. Epub 2009 Apr 23. Erratum in: Diabetes Care. 2009 Oct;32(10):1944. PMID: 19389820 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.

    Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV.

    Diabetes Care. 2004 Jul;27(7):1554-8.PMID: 15220227 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    10.

    Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.

    Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW; Insulin Aspart CSII/MDI Comparison Study Group.

    Diabetes Care. 2005 Mar;28(3):533-8.PMID: 15735183 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.

    Roach P, Bai S, Charbonnel B, Consoli A, Taboga C, Tiengo A, Bolli G; High Mix Study Group.

    Clin Ther. 2004 Apr;26(4):502-10.PMID: 15189747 [PubMed - indexed for MEDLINE]Related articles

    12.

    Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study.

    Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR.

    Diabetes Care. 2003 Sep;26(9):2598-603.PMID: 12941725 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system.

    Bode BW, Steed RD, Schleusener DS, Strange P.

    Endocr Pract. 2005 May-Jun;11(3):157-64.PMID: 16239201 [PubMed - indexed for MEDLINE]Related articles

    14.

    Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion.

    Wittlin SD, Marcus AO, Weng CS, Howard CP, Schorr AB; CONTROL Study Group.

    Diabetes Technol Ther. 2008 Feb;10(1):1-10.PMID: 18275357 [PubMed - indexed for MEDLINE]Related articles

    15.

    Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

    Clin Ther. 2007 Nov;29(11):2374-84.PMID: 18158078 [PubMed - indexed for MEDLINE]Related articles

    16.

    Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.

    Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L.

    Diabetes Care. 2000 May;23(5):583-8.PMID: 10834413 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.

    Launay B, Zinman B, Tildesley HD, Strack T, Chiasson JL.

    Diabetes Care. 1998 Oct;21(10):1627-31.PMID: 9773721 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.

    Hamann A, Matthaei S, Rosak C, Silvestre L; HOE901/4007 Study Group.

    Diabetes Care. 2003 Jun;26(6):1738-44.PMID: 12766103 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.

    Attia N, Jones TW, Holcombe J, Tamborlane WV.

    Diabetes Care. 1998 May;21(5):817-21.PMID: 9589247 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps.

    Melki V, Renard E, Lassmann-Vague V, Boivin S, Guerci B, Hanaire-Broutin H, Bringer J, Belicar P, Jeandidier N, Meyer L, Blin P, Augendre-Ferrante B, Tauber JP.

    Diabetes Care. 1998 Jun;21(6):977-82.PMID: 9614617 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity